HRP20020995A2 - Purine derivatives - Google Patents

Purine derivatives Download PDF

Info

Publication number
HRP20020995A2
HRP20020995A2 HR20020995A HRP20020995A HRP20020995A2 HR P20020995 A2 HRP20020995 A2 HR P20020995A2 HR 20020995 A HR20020995 A HR 20020995A HR P20020995 A HRP20020995 A HR P20020995A HR P20020995 A2 HRP20020995 A2 HR P20020995A2
Authority
HR
Croatia
Prior art keywords
amino
formula
compound
alkyl
ethyl
Prior art date
Application number
HR20020995A
Other languages
English (en)
Croatian (hr)
Inventor
John Mantell Simon
Marina Monaghan Sandra
Thomas Stephenson Peter
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20020995A2 publication Critical patent/HRP20020995A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
HR20020995A 2000-06-27 2001-06-14 Purine derivatives HRP20020995A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015727.1A GB0015727D0 (en) 2000-06-27 2000-06-27 Purine derivatives
PCT/IB2001/001064 WO2002000676A1 (en) 2000-06-27 2001-06-14 Purine derivatives

Publications (1)

Publication Number Publication Date
HRP20020995A2 true HRP20020995A2 (en) 2005-02-28

Family

ID=9894500

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020995A HRP20020995A2 (en) 2000-06-27 2001-06-14 Purine derivatives

Country Status (43)

Country Link
EP (1) EP1296996B1 (pl)
JP (1) JP2004501929A (pl)
KR (1) KR20030036248A (pl)
CN (1) CN1432020A (pl)
AP (1) AP1372A (pl)
AR (1) AR028759A1 (pl)
AT (1) ATE267836T1 (pl)
AU (1) AU2001264164A1 (pl)
BG (1) BG107171A (pl)
BR (1) BR0111912A (pl)
CA (1) CA2412564C (pl)
CZ (1) CZ20023992A3 (pl)
DE (1) DE60103537T2 (pl)
DK (1) DK1296996T3 (pl)
DO (1) DOP2001000195A (pl)
EA (1) EA200201291A1 (pl)
EC (1) ECSP024396A (pl)
EE (1) EE200200712A (pl)
ES (1) ES2220775T3 (pl)
GB (1) GB0015727D0 (pl)
GT (1) GT200100119A (pl)
HR (1) HRP20020995A2 (pl)
HU (1) HUP0301389A3 (pl)
IL (1) IL152529A0 (pl)
IS (1) IS6580A (pl)
MA (1) MA26918A1 (pl)
MX (1) MXPA03000078A (pl)
NO (1) NO20025975L (pl)
NZ (1) NZ521867A (pl)
OA (1) OA12294A (pl)
PA (1) PA8521001A1 (pl)
PE (1) PE20020213A1 (pl)
PL (1) PL361384A1 (pl)
PT (1) PT1296996E (pl)
PY (1) PY0115244A (pl)
SI (1) SI1296996T1 (pl)
SK (1) SK17332002A3 (pl)
SV (1) SV2002000507A (pl)
TN (1) TNSN01096A1 (pl)
TR (1) TR200401622T4 (pl)
UY (1) UY26797A1 (pl)
WO (1) WO2002000676A1 (pl)
ZA (1) ZA200209557B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60215028T2 (de) 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
WO2004028530A1 (en) 2002-09-26 2004-04-08 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
BRPI0515506A (pt) * 2004-09-20 2008-07-29 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso dos mesmos
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ATE549337T1 (de) * 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
KR20090075714A (ko) 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
EP2231642B1 (en) 2008-01-11 2013-10-23 Novartis AG Pyrimidines as kinase inhibitors
US8148503B2 (en) 2008-06-11 2012-04-03 Lasergen, Inc. Nucleotides and nucleosides and methods for their use in DNA sequencing
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MY162604A (en) 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
IL107101A0 (en) * 1992-09-30 1993-12-28 Merrell Dow Pharma 2-substituted adenosines with a-2 receptor affinity
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
EP1044004A1 (en) * 1998-01-08 2000-10-18 The University Of Virginia Patent Foundation A2a adenosine receptor agonists in combination with a type iv phosphodiesterase inhibitors
BR9914526A (pt) * 1998-10-16 2001-07-03 Pfizer Derivados de adenina
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9924361D0 (en) * 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
HUP0301389A2 (hu) 2003-08-28
NZ521867A (en) 2004-04-30
SV2002000507A (es) 2002-07-03
PE20020213A1 (es) 2002-03-19
TR200401622T4 (tr) 2004-08-23
DOP2001000195A (es) 2002-05-15
MXPA03000078A (es) 2003-08-19
PA8521001A1 (es) 2002-04-25
KR20030036248A (ko) 2003-05-09
SI1296996T1 (en) 2004-10-31
UY26797A1 (es) 2002-01-31
GB0015727D0 (en) 2000-08-16
BG107171A (bg) 2003-07-31
JP2004501929A (ja) 2004-01-22
SK17332002A3 (sk) 2004-03-02
CA2412564A1 (en) 2002-01-03
AU2001264164A1 (en) 2002-01-08
PL361384A1 (pl) 2004-10-04
GT200100119A (es) 2002-01-31
AR028759A1 (es) 2003-05-21
NO20025975D0 (no) 2002-12-12
OA12294A (en) 2003-11-14
EP1296996A1 (en) 2003-04-02
IL152529A0 (en) 2003-05-29
CZ20023992A3 (cs) 2003-12-17
EA200201291A1 (ru) 2003-04-24
ES2220775T3 (es) 2004-12-16
CA2412564C (en) 2007-10-02
HUP0301389A3 (en) 2005-02-28
ATE267836T1 (de) 2004-06-15
TNSN01096A1 (fr) 2005-11-10
PY0115244A (es) 2003-11-03
NO20025975L (no) 2002-12-12
PT1296996E (pt) 2004-08-31
IS6580A (is) 2002-10-10
ECSP024396A (es) 2003-02-06
DE60103537T2 (de) 2005-07-07
ZA200209557B (en) 2003-12-02
MA26918A1 (fr) 2004-12-20
DK1296996T3 (da) 2004-08-16
WO2002000676A1 (en) 2002-01-03
DE60103537D1 (de) 2004-07-01
AP1372A (en) 2005-02-21
CN1432020A (zh) 2003-07-23
EE200200712A (et) 2004-06-15
EP1296996B1 (en) 2004-05-26
BR0111912A (pt) 2003-05-13

Similar Documents

Publication Publication Date Title
ES2220775T3 (es) Derivados de purina.
AU2001260537B2 (en) 2-aminocarbonyl-9H-purine derivatives
US6350735B1 (en) Purine derivatives
US6525032B2 (en) Purine derivatives
AU764106B2 (en) Purine derivatives
US6448236B1 (en) Purine derivatives
US20020032168A1 (en) Purine derivatives
US6753322B2 (en) 2-aminocarbonyl-9H-purine derivatives

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn